EGFR and breast cancer: Interestingly, activation of PI3K-AKT-mTOR signaling in our data agrees well with clinical evidence showing that some breast cancer patients develop drug resistance after being treated with EGFR inhibitors, and that compensatory signaling via the PI3K-AKT-mTOR pathway has been implicated in such resistance [32]–[34].